Biotechnology company Moderna, Inc. (NASDAQ: MRNA) Thursday reported a sharp decline in revenues for the second quarter of 2024.
- Second-quarter revenues decreased to $241 million from $344 million in the prior-year period
- Net loss narrowed to $1.28 billion or $3.33 per share in Q2 from $1.38 billion or $3.62 per share a year earlier
- Net product sales for the quarter were $184 million, reflecting a 37% decrease from the same period in 2023
- For fiscal 2024, the company expects total product sales to be between $3.0 billion and $3.5 billion
- Full-year cost of sales is expected to be in the range of 40-50% of product sales
- Q2 cost of sales was $115 million, including third-party royalties unutilized manufacturing capacity & wind-down costs, and inventory write-downs
- Cash, cash equivalents, and investments as of June 30, 2024, were $10.8 billion, vs. $12.2 billion as of March 31, 2024
Listen to the conference calls as they happen. Don't miss a beat! With AlphaStreet Intelligence, you can listen to live calls and interviews as they happen, so you never have to worry about missing out on important information.
Most Popular
KB Home’s Q3 results expected to benefit from built-to-order model, stable demand
KB Home (NYSE: KBH) has been resilient to challenges like high mortgage rates and the inflation-induced strain on family budgets, while benefitting from the recovery in the housing market. When
Signet Jewelers (SIG) reports lower Q2 2025 sales and adj. profit
Signet Jewelers Limited (NYSE: SIG) has reported a decline in net sales and adjusted earnings for the second quarter of 2025. Same-store sales declined 3.4% during the three months. Net
Adobe reports higher Q3 revenue and earnings; results beat estimates
Design software maker Adobe Inc. (NASDAQ: ADBE) on Thursday reported an increase in third-quarter 2024 revenue and earnings. The results also topped expectations. Third-quarter revenues came in at $5.41 billion,
